Related Experiment Video
Updated: May 14, 2026
15:15
Flow Cytometry Analysis of Immune Cells Within Murine Aortas
Published on: July 1, 2011
T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated
M M Ewing1, J C Karper, S Abdul
1Dept. of Cardiology, Leiden University Medical Center (LUMC), Leiden, The Netherlands; Dept. of Surgery, LUMC, Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands.
International Journal of Cardiology
|January 29, 2013
Summary
T-cells drive accelerated atherosclerosis after interventions. Blocking T-cell co-stimulation with abatacept significantly reduced lesion development, highlighting its therapeutic potential for preventing post-procedural vascular remodeling.
Area of Science:
- Immunology
- Cardiovascular Biology
- Vascular Biology
Background:
- T-cells are crucial in native atherosclerosis development.
- Post-interventional accelerated atherosclerosis involves complex immune responses.
- The roles of CD28-CD80/86 co-stimulation and CTLA-4 co-inhibition in T-cell activation require further elucidation.
Purpose of the Study:
- To investigate T-cell involvement in accelerated atherosclerosis post-intervention.
- To examine the function of CD28-CD80/86 and CTLA-4 pathways in regulating T-cell activation during this process.
Main Methods:
- A femoral artery cuff mouse model was used to study post-interventional remodeling.
- Investigated roles of T-cells, CD28-CD80/86, and CTLA-4 pathways.
- Utilized genetic knockouts (CD4-/-, CD80-/-, CD86-/-), abatacept treatment, and CTLA-4 blocking antibodies.
Main Results:
- Reduced intimal lesions were observed in CD4(-/-) and CD80(-/-)CD86(-/-) mice.
- Abatacept treatment significantly reduced intimal thickening and accelerated atherosclerosis development.
- Abatacept prevented CD4 T-cell activation and modulated cytokine profiles (IFN-γ, IL-10).
- CTLA-4 blockade exacerbated vascular lesion size.
Conclusions:
- T-cell CD28-CD80/86 co-stimulation is essential for post-interventional accelerated atherosclerosis.
- CTLA-4 co-inhibition regulates this T-cell activation.
- Abatacept shows promise for preventing post-interventional vascular remodeling.
Related Concept Videos
01:38Inflammation
Overview
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...